The U.S. Supreme Court declined to take up lawsuits challenging Medicare prescription drug price negotiations under the Inflation Reduction Act, including petitions tied to AstraZeneca and multiple other major drugmakers. The court’s denial effectively ends that specific legal campaign for now because the justices did not review the cases. The earlier lower-court losses left no circuit split argument, and the Supreme Court typically avoids intervening when appellate courts agree. The brief also notes that only limited response was provided by companies as of publication. The decision reinforces that IRA negotiations remain the operative policy framework, shaping pricing planning, launch strategy, and pipeline valuation across large pharma and biopharma participants with Medicare exposure.